Agendia Licenses RNARetain(TM) as Accessory to MammaPrint(R).Agendia Accesses Asuragen's Proprietary Pre-Analytical Solution for Tissue Preservation for Use with Agendia's Breast Cancer Profiling Test AUSTIN, Texas & AMSTERDAM, The Netherlands -- Asuragen, Inc., an oncology molecular diagnostic company and molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller service provider, today announced it has granted a non-exclusive license to Agendia, B.V., a gene expression analysis-based diagnostics and clinical testing company. Under the terms of this agreement, Agendia has the right to use RNARetain globally for human diagnostic applications. "We are very excited about having RNARetain used in conjunction with MammaPrint. The tissue preservative preservative Any of numerous chemical additives used to prevent or slow food spoilage caused by chemical changes (e.g., oxidation, mold growth) and maintain a fresh appearance and consistency. Antimycotics (e.g. solution, has found widespread clinical application and is uniquely suited for preserving nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. profiles in solid tissues, both normal and cancerous, for subsequent clinical testing," said Matt Winkler Winkler may refer to:
RNARetain, also known as RNAlater(TM) in the life sciences market, is a patented technology useful for stabilizing expression profiles, of both RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic and DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. , in tissues and cells. "Access to RNARetain will provide Agendia with the opportunity to use a convenient shipping method. This allows us to offer our high quality analyses of tumor samples, like MammaPrint, around the globe," explained Dr. Bernhard Sixt, CEO of Agendia. Agendia's MammaPrint is a validated molecular-diagnostic test based on gene expression profiling of 70 genes that form a reliable predictor of the risk of cancer recurrence in individual breast cancer patients. About Asuragen, Inc. Asuragen is a fully integrated diagnostic reagent company focused on molecular oncology and early detection of cancer, with emphasis on microRNA. Asuragen's current product portfolio consists of Signature([R]) Genetic Testing Genetic Testing Definition A genetic test examines the genetic information contained inside a person's cells, called DNA, to determine if that person has or will develop a certain disease or could pass a disease to his or her offspring. and Oncology Testing products, as well as industry leading controls and standards engineered using its patented Armored RNA([R]) technology. Asuragen is empowered with not only a high level of scientific expertise, but also assay development, business infrastructure, GLP See gateway location protocol. testing services and an established cGMP manufacturing facility that allow it to span the spectrum of discovery, testing, production and commercialization. Asuragen is dedicated to developing new technologies that will become cutting edge clinical products. RNAlater is a trademark of Ambion, Inc. For more information, visit www.asuragen.com About Agendia, B.V. Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test - MammaPrint([R]) - that predicts the risk of breast cancer recurrence. Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology. For more information, visit www.agendia.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion